Company intelligence / Profile preview

Nymirum

Durham, North Carolina, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Nymirum developed a proprietary platform for RNA-targeting small molecules, with preclinical results showing the ability to identify drug-like small molecules that bind CUG repeat RNAs and normalize mis-splicing in myotonic dystrophy type 1 cell models. Further lead optimization and broader discovery campaigns were reportedly ongoing as of 2020-2021.

Therapeutic areas: NeurologyRare Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Servier (strategic collaboration to identify and develop RNA-modulatory drugs)

Beyond the preview

Go deeper on Nymirum.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nymirum.

Explore the full profile